502 patents
Utility
Bifunctional Degraders of Hematopoietic Progenitor Kinase and Therapeutic Uses Thereof
18 Jan 24
The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
John Buell, Frederick Cohen, Ryan Pemberton, Hunter P. Shunatona, Lan Wang, Mark Edward Zak
Filed: 9 Nov 22
Utility
Methods for Treatment of Viral Infections
11 Jan 24
The present disclosure relates to methods for treating viral infections in a patient that is not pregnant.
Roy Maxim Bannister, John P. Bilello, Jared D. Pitts
Filed: 5 Jun 23
Utility
Tetracyclic Compounds and Uses Thereof
11 Jan 24
The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions.
Lan Jiang, David W. Lin, Michael L. Mitchell, Ezra Roberts, Gregg M. Schwarzwalder
Filed: 12 May 23
Utility
Lpa Receptor Antagonists and Uses Thereof
4 Jan 24
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1.
Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
Filed: 24 May 23
Utility
GLP-1R modulating compounds
2 Jan 24
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof.
Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
Filed: 19 Apr 22
Utility
Engineered CD200R Antibodies and Uses Thereof
28 Dec 23
In some aspects, provided herein are antibodies or antigen-binding fragments that bind to CD200R, a glycoprotein receptor present on cell surfaces.
Simon John DAVIS, Richard John CORNALL, Christopher Douglas PALUCH, Lynne Anne MURRAY, Nathan Jacob ROBERTSON, Eleanor Marysia SCOTT, Daniela M. TOMAZELA
Filed: 5 Apr 23
Utility
Diacylglycerol kinase modulating compounds
19 Dec 23
The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection.
Masaaki Sawa, Mai Arai, Ryoko Nakai, Hirokazu Matsumoto, Catherine Pugh, Eric Hu, Juan Guerrero, Jesse Jacobsen, Jonathan William Medley, Jie Xu, Latesh Lad, Leena Patel, Michael Graupe, Qingming Zhu, Stephen Holmbo, Tetsuya Kobayashi, Will Watkins, Yasamin Moazami, Suet C. Yeung, Julian A. Codelli, Heath A. Weaver
Filed: 18 Dec 20
Utility
Process for preparing a Cot inhibitor compound
19 Dec 23
Kevin M. Allan, Lina Chan, Andrei Chtchemelinine, Jeffrey T. Deignan, Kassibla E. Dempah, Kelly J. Eberle, Danielle M. Elfgren, Timothy G. Elford, Kevin D. Haggerty, Jesse W. Li, Tianmin Niu, Andrew C. Stevens, Ana F. Voica, Kevin S. Williamson, Boran Xu, Guojun Yu
Filed: 31 Mar 21
Utility
Solid forms of an HIV capsid inhibitor
19 Dec 23
The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yOpyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
Bing Shi
Filed: 26 Jan 22
Utility
Compounds and methods for treatment of viral infections
19 Dec 23
Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
Mark J. Bartlett, Daniel H. Byun, Yifan Deng, Jennifer L. Cosman Ellis, Rao V. Kalla, Richard L. Mackman, Dustin S. Siegel, Xianhuang Zeng
Filed: 6 Mar 23
Utility
GLP-1R Modulating Compounds
7 Dec 23
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof.
Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
Filed: 10 May 23
Utility
Choline salt forms of an HIV capsid inhibitor
5 Dec 23
The present disclosure relates to choline salts, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfony)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)- 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus.
Travis Lee Houston, Bing Shi
Filed: 26 Jan 22
Utility
Methods of treating liver disease
5 Dec 23
The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ACC inhibitor in combination with an FXR agonist to a patient in need thereof.
Jamie Geier Bates, David Gordon Clarkson Breckenridge, John T. Liles
Filed: 27 Feb 20
Utility
Antiviral Compounds and Methods of Making and Using the Same
30 Nov 23
Antiviral compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
Byoung-Kwon Chun, Michael O. Clarke, Deeba Ensan, Rao V. Kalla, Richard L. Mackman, Devan Naduthambi, Dustin S. Siegel
Filed: 1 Mar 23
Utility
Toll like receptor modulator compounds
28 Nov 23
This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g.
Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
Filed: 11 Aug 21
Utility
Cot modulators and methods of use thereof
28 Nov 23
The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
Eda Y. Canales, Manoj C. Desai, Eric Gorman, Jiayao Li, Roland D. Saito, James G. Taylor, Nathan E. Wright
Filed: 7 Apr 22
Utility
Ikaros Zinc Finger Family Degraders and Uses Thereof
23 Nov 23
The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos).
Gayatri Balan, Peter A. Blomgren, Chen Chen, Julian A. Codelli, Zhimin Du, Musong Kim, Dorothée Saddier Axe, Gregg M. Schwarzwalder, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani, William J. Watkins, Brian M. Weist, Suet C. Yeung, Helen Yu
Filed: 15 Mar 23
Utility
Kras G12D Modulating Compounds
23 Nov 23
Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
Chaodi Dai, Juan A. Guerrero, Tezcan Guney, Hongyan Guo, Darryl Kato, Irene N. Kiburu, Scott E. Lazerwith, Jessica L. McKinley, Jonathan William Medley, Hyung-Jung Pyun, Maoqun Tian, Vickie H. Tsui, William J. Watkins, Adam D. Zajdlik, Jennifer R. Zhang
Filed: 20 Apr 23
Utility
Antiviral Pyrazolopiridinone Compounds
16 Nov 23
Zef Konst, Yipin Lu, Robert Joseph Moreau, Naomi Samadara Rajapaksa, Galen Shearn-Nance, David Charles Tully, Michael Robert Turner, Joseph Michael Young, Qian Zhao, Britton K. Corkey, Samuel E. Metobo
Filed: 6 Feb 23
Utility
Combination Therapy for Treating Colorectal Cancer
16 Nov 23
Provided are methods of treating colorectal cancer in a subject comprising co-administering to the subject an effective amount of: (a) an agent that inhibits binding between CD47 and SIRPα (e.g., magrolimab); and (b) an agent that inhibits binding between vascular endothelial growth factor A (VEGFA) and one or more VEGFA cognate receptors (e.g., bevacizumab), optionally further including a chemotherapy regimen (e.g., FOLFIRI).
Mark P. Chao, William J. Grossman, Fatema A. Legrand
Filed: 3 Apr 23